NCT00003209 is a Phase 3 clinical trial of bleomycin sulfate in Cervical Cancer, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

Who is sponsoring NCT00003209?

NCT00003209 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What drugs are being tested in NCT00003209?

Interventions in NCT00003209: bleomycin sulfate, cisplatin, fluorouracil, ifosfamide, methotrexate, mitomycin C, vinblastine sulfate, vindesine, radiation therapy.

What condition does NCT00003209 study?

NCT00003209 studies Cervical Cancer.

Is NCT00003209 still recruiting?

NCT00003209 is currently completed. Last updated 10 July 2012.

Last reviewed 2012-07-10 · How we verify

NCT00003209

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer

Completed Phase 3 Last updated 10 July 2012

What this trial tests

Phase 3 trial testing bleomycin sulfate in Cervical Cancer in 700 participants. Completed.

Timeline

1 December 1997

Primary endpoint
1 December 1999

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	700
Start date	1 December 1997
Primary completion	1 December 1999
Sites	2 locations across United Kingdom

Drugs / interventions tested

bleomycin sulfate — full drug profile →
cisplatin (cisplatin) — full drug profile →
fluorouracil — full drug profile →
ifosfamide
methotrexate
mitomycin C
vinblastine sulfate
vindesine (VINDESINE) — full drug profile →
radiation therapy

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known whether giving radiation therapy with chemotherapy after surgery is more effective than radiation therapy alone after surgery in treating cervical cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy after surgery in treating patients with stage IB or stage IIA cervical cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of bleomycin sulfate

Trials testing the same drug.

NCT01026220 — Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma · Phase 3 · completed
NCT00678327 — Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Sta · Phase 3 · completed
NCT00104676 — Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors · Phase 3 · completed
NCT00053352 — Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors · Phase 3 · completed
NCT00002565 — Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma · Phase 3 · completed

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other European Organisation for Research and Treatment of Cancer - EORTC trials

Trials by the same sponsor.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT06978062 — Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment · Phase 1 · not yet recruiting
NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00003209 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
Last refreshed: 10 July 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing